BSE Archives - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Syngene's operations in the Indian city of Hyderabad have been transferred to another wholly-armed arm of the company with effect from April 1, 2023, for a value of INR 4 billion, according to a BSE filing.

Syngene buys Hyderabad operations in slump sale value of INR 4 billion

Syngene's operations in the Indian city of Hyderabad have been transferred to another wholly-armed arm of the company with effect from April 1,.

by HealthQuill
January 31, 2023
0 Comments

Pharma

USFDA inspects Alembic’s pharma facility in Gujarat

HT Team October 18, 2022: The USFDA has inspected India’s Alembic Pharmaceuticals’ Oncology Injectable Formulation Facility at Panelav, Gujarat, according to a BSE.

by HealthQuill
October 18, 2022
0 Comments